Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease.
| Autor: | Malanda A; IDD, Sanofi, 1 av Pierre Brossolette, F-91935 Chilly Mazarin, France., Abécassis PY; DSAR, Sanofi, 13 quai Jules Guesde, F-94403 Vitry-sur-Seine, France., Barnéoud P; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, F-91935 Chilly Mazarin, France., Brunel P; Preclinical safety, Sanofi, 3, digue d' Alfortville, F- 94140 Alfortville, France., Taupin V; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, F-91935 Chilly Mazarin, France., Vigé X; Translational Science, Sanofi, 1 av Pierre Brossolette, F-91935, Chilly Mazarin, France., Lesuisse D; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, F-91935 Chilly Mazarin, France. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Data in brief [Data Brief] 2019 May 27; Vol. 27, pp. 104057. Date of Electronic Publication: 2019 May 27 (Print Publication: 2019). |
| DOI: | 10.1016/j.dib.2019.104057 |
| Abstrakt: | This article describes the chemical synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel Nurr1/NOT agonist. It is meant as a support to an article recently published in Bioorganic and Medicinal chemistry Letters and entitled "Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease" [1] and presenting the discovery, scope and potential of these new ligands of these nuclear receptors. (© 2019 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|